Cellosaurus logo
expasy logo

Cellosaurus RT4rCDDP1000 (CVCL_RR19)

[Text version]
Cell line name RT4rCDDP1000
Accession CVCL_RR19
Resource Identification Initiative To cite this cell line use: RT4rCDDP1000 (RRID:CVCL_RR19)
Comments Part of: Resistant Cancer Cell Line (RCCL) collection.
Population: Caucasian.
Doubling time: 39.6 hours (PubMed=26055179).
Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  • Mutation; HGNC; 12362; TSC1; Simple; p.Leu557Cysfs*72 (c.1669delC); ClinVar=VCV000048811; Zygosity=Homozygous (from parent cell line).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0036 (RT-4)
Sex of cell Male
Age at sampling 63Y
Category Cancer cell line
Web pages https://www.wass-michaelislab.org/rccl.php

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

Cell line databases/resources cancercelllines; CVCL_RR19
Encyclopedic resources Wikidata; Q54951365
Entry history
Entry creation05-Mar-2018
Last entry update05-Oct-2023
Version number11